ARS-1620   Click here for help

GtoPdb Ligand ID: 10383

Synonyms: ARS1620 | example 227 [US9840516B2]
PDB Ligand
Compound class: Synthetic organic
Comment: ARS-1620 was designed to target mutated KRASG12C in cancer [1]. It binds covalently to GDP-bound KRASG12C and traps it in the inactive conformation. Structurally ARS-1620 is the S-atropisomer. It represents a pharmacological tool that is suitable for use in in vitro and in vivo experiments to further explore KRAS dependency in KRAS mutant cancers. The chemical structure is claimed in Araxes Pharma's patent US9840516B2
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 69.56
Molecular weight 430.1
XLogP 4.34
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCN(CC1)c1ncnc2c1cc(Cl)c(c2F)c1c(O)cccc1F
Isomeric SMILES C=CC(=O)N1CCN(CC1)c1ncnc2c1cc(Cl)c(c2F)c1c(O)cccc1F
InChI InChI=1S/C21H17ClF2N4O2/c1-2-16(30)27-6-8-28(9-7-27)21-12-10-13(22)17(19(24)20(12)25-11-26-21)18-14(23)4-3-5-15(18)29/h2-5,10-11,29H,1,6-9H2
InChI Key ZRPZPNYZFSJUPA-UHFFFAOYSA-N
Bioactivity Comments
ARS-1620 inhibits RAS signalling in vitro with an IC50 of 120 nM, whereas the R-atropisomer is inactive in the same assays [1]. It is effictive as a single agent in cell line- and patient-derived mouse xenograft models of KRASG12C-driven cancer .
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
KRAS Primary target of this compound Hs Inhibitor Inhibition 6.9 pIC50 - 1
pIC50 6.9 (IC50 1.2x10-7 M) [1]
Description: Inhibition of KRAS G12C signalling in vitro.